New treatment for MOG antibody disease using nanoparticles
Novel immunotherapy against MOG antibody disease
This study is testing a new treatment for MOG antibody disease that uses tiny particles to help your immune system learn to tolerate the disease better, with the hope of providing a safer option than current medications like steroids.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Evoq Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11007654 on NIH RePORTER |
What this research studies
This research focuses on developing a novel immunotherapy for Myelin oligodendrocyte glycoprotein (MOG) antibody disease, a rare neurological disorder. The approach involves using synthetic high-density lipoprotein NanoDiscs to deliver specific antigen peptides to lymph nodes, aiming to induce immune tolerance and modify the disease. Current treatments involve steroids and immunosuppressants, which can have significant side effects, highlighting the need for safer, targeted therapies. The research builds on promising preliminary data from animal models that suggest this method could effectively treat MOGAD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with MOG antibody disease who are experiencing symptoms such as vision loss or spinal cord damage.
Not a fit: Patients with other neurological disorders not related to MOG antibody disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients with MOG antibody disease.
How similar studies have performed: Other research has shown success with nanoparticle-based therapies in autoimmune diseases, indicating potential for this novel approach.
Where this research is happening
Ann Arbor, United States
- Evoq Therapeutics, INC. — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Daniel, Weston — Evoq Therapeutics, INC.
- Study coordinator: Daniel, Weston
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.